Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambalalrabhai EnterprisesBOM:500009 +0.13%65 Pretax Margin % is 9.55% as of Mar. 2026, which is 24% above its 10-year median of 7.68. GuruFocus rates BOM:500009 with a GF Score™ of 65/100 and a GF Value™ of ₹41.72 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Ambalalrabhai Enterprises ranks better than 55.58% on this metric.
The historical rank and industry rank for Ambalalrabhai Enterprises's Pretax Margin % or its related term are showing as below:
BOM:500009'
s Pretax Margin % Range Over the Past 10 Years
Min: -10.17 Med: 7.68 Max: 27.81
Current: 9.15
BOM:500009's Pretax Margin % is ranked better than 55.58% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs BOM:500009: 9.15
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ambalalrabhai Enterprises Pretax Margin % Related Terms
Ambalalrabhai Enterprises Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500009 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ambalalrabhai Enterprises's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambalalrabhai Enterprises Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ambalalrabhai Enterprises's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ambalalrabhai Enterprises's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambalalrabhai Enterprises (BOM:500009) has a Pretax Margin % of 9.55% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ambalalrabhai Enterprises and its competitors. This is 24% above median its historical median of 7.68. According to the industry distribution chart, Ambalalrabhai Enterprises ranks #426 out of 959 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Ambalalrabhai Enterprises' Pretax Margin % too high?
Ambalalrabhai Enterprises' current Pretax Margin % of 9.55% is 24% above median its 10-year median of 7.68. The Drug Manufacturers industry median Pretax Margin % is 7.29. Ambalalrabhai Enterprises' value of 9.55% is 31% above this industry median. Based on the distribution chart, Ambalalrabhai Enterprises ranks #426 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ambalalrabhai Enterprises has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambalalrabhai Enterprises' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ambalalrabhai Enterprises ranks #426 out of 959 companies for Pretax Margin %. This puts Ambalalrabhai Enterprises in the upper half of its industry. The industry median Pretax Margin % is 7.29. Ambalalrabhai Enterprises' value of 9.55% is 31% above this benchmark. While the company's 10-year median is 7.68 vs. the industry median of 7.29, Ambalalrabhai Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambalalrabhai Enterprises's current Pretax Margin % of 9.55% is 31% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ambalalrabhai Enterprises and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambalalrabhai Enterprises's current Pretax Margin % is 9.55%, which is 24% above median its own 10-year median of 7.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambalalrabhai Enterprises stock overvalued right now?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises (BOM:500009) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.72, compared to a current price of ₹31.00 — trading 25.7% below its estimated fair value. The current Pretax Margin % is 9.55%, which is 24% above median its 10-year median of 7.68 and 31% above the Drug Manufacturers industry median of 7.29. Ambalalrabhai Enterprises' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ambalalrabhai Enterprises (BOM:500009), the current Pretax Margin % is 9.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambalalrabhai Enterprises (BOM:500009) Overvalued in 2026?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises stock appears to be undervalued.
The current stock price of ₹31.00 is trading 25.7% below its estimated GF Value™ of ₹41.72.
GuruFocus considers Ambalalrabhai Enterprises to be Modestly Undervalued.
Key valuation signals for BOM:500009:
Pretax Margin %: 9.55% (24% above median its 10-year median of 7.68)
GF Value™: ₹41.72 vs. price of ₹31.00 (25.7% below fair value)
Industry Position: 31% above the Drug Manufacturers median (#426 of 959)
No single metric tells the full story. See the BOM:500009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambalal Sarabhai Enterprises Ltd is an India-based company engaged in the manufacturing and marketing of Drugs and Formulation. The operating segment of the company is Pharmaceutical Products. It serves domestic as well as International markets.
65GF Score
Get the complete analysis for BOM:500009
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500009 has been successfully added to your 
